Atara Biotherapeutics Faces Securities Class Action Lawsuit

A securities fraud class action lawsuit has been filed against Atara Biotherapeutics (NASDAQ: ATRA) on behalf of investors who purchased shares between May 20, 2024 and January 9, 2026. The suit alleges that the company misrepresented regulatory prospects for its T-cell immunotherapy tabelecleucel by concealing manufacturing issues and flawed clinical trials. These disclosures led to sharp declines in ATRA's stock price.

By Levi & Korsinsky · Auto-Fetched Original Sources · March 25, 2026, 16:35 UTC

Tickers: $ATRA

Topics: class action FDA approval issues stock price drop

Read the full article at Auto-Fetched Original Sources

More Politics news

Scott Colom Defeats Incumbent Cindy Hyde-Smith in Mississippi Senate Election CNBC · November 11, 2026, 23:03 UTC
Advocacy Groups Prepare to Pressure Politicians Over Data Center Restrictions Following Midterm Elections The Verge · November 11, 2026, 21:56 UTC
Alleged Security Concerns Involving Nvidia CEO Jensen Huang Prompt US-Taiwan Official Concern The Verge · November 11, 2026, 19:22 UTC
Scott Colom Maintains Narrow Lead Over Cindy Hyde-Smith in Mississippi Senate Race CNBC · November 10, 2026, 21:55 UTC
Jim Jordan Elected House Republican Minority Leader CNBC · November 10, 2026, 19:55 UTC
President Trump Replaces WeatherTech Founder with Agency Veteran for FTC Nomination The Verge · November 10, 2026, 14:46 UTC
Republican Leadership Divided Over Causes of Midterm Election Losses CNBC · November 10, 2026, 11:00 UTC
Donald Trump Makes Unannounced C-SPAN Appearance Following Midterm Election Losses CNBC · November 10, 2026, 06:19 UTC
Bipartisan American Affordability and Jobs Act (BAAJA) Gains Momentum in Senate The Verge · November 9, 2026, 23:49 UTC
House Republican Committee Chairs Request Closed-Door Briefing with Nvidia CEO Jensen Huang The Verge · November 9, 2026, 20:21 UTC